BASICS OF DEVELOPMENT OF NEW ANTIFUNGAL AGENTS IN OPHTHALMOLOGY: A REVIEW
DOI:
https://doi.org/10.22159/ijap.2026v18i1.55104Keywords:
Antifungal agents, Fungal keratitis, Treatment, Bioavailability, Side effectsAbstract
The aim of this work was to study the status of treatment of fungal eye infections. Recent data indicate a steady rise in diagnosed cases of fungal ocular diseases, particularly fungal keratitis-especially in developing countries. In some regions, the absence of locally available antifungal medications, despite increasing demand, contributes to this trend. Despite prolonged observation and efforts to combat fungal eye diseases, the global availability of antifungal drugs remains limited, especially for local use. These drugs are an integral part of comprehensive treatment, along with systemic drugs. The objective of this review work is to conduct a comparative analysis of molecules that have been evaluated in terms of antifungal activity, bioavailability, efficacy, and safety, considering the long duration of treatment and, consequently, increased risks of side effects.
For this purpose, a comprehensive review was conducted of materials published between 2015 and 2025 in international scientific databases, including PubMed, Scopus, Google Scholar, and ResearchGate. The search strategy was designed to capture relevant studies on antifungal ophthalmic therapies, dosage forms, and active pharmaceutical ingredients used in the treatment of fungal keratitis. Based on the reviewed literature, a SWOT analysis was performed, for the first time in this context, to systematically evaluate the strengths, weaknesses, opportunities, and threats associated with the principal dosage forms of ophthalmic antifungal drugs. This novel analytical approach enabled the identification of key directions for enhancing therapeutic efficacy, improving formulation design, and addressing clinical and regulatory gaps in the management of fungal ocular infections. The presented data can serve as a foundation for the development of improved drug formulations and delivery systems targeted directly to the affected ocular tissues-without preservatives, with controlled drug release-thereby enhancing treatment effectiveness, minimizing drug loss, and reducing patient risks associated with side effects and antifungal resistance. Furthermore, these advancements have the potential to significantly improve patient quality of life and increase the likelihood of full recovery, without irreversible visual impairment.
For this purpose, a comprehensive review was conducted of materials published between 2015 and 2025 in international scientific databases, including PubMed, Scopus, Google Scholar, and ResearchGate. The search strategy was designed to capture relevant studies on antifungal ophthalmic therapies, dosage forms, and active pharmaceutical ingredients used in the treatment of fungal keratitis. Based on the reviewed literature, a SWOT analysis was performed, for the first time in this context, to systematically evaluate the strengths, weaknesses, opportunities, and threats associated with the principal dosage forms of ophthalmic antifungal drugs. This novel analytical approach enabled the identification of key directions for enhancing therapeutic efficacy, improving formulation design, and addressing clinical and regulatory gaps in the management of fungal ocular infections. The presented data can serve as a foundation for the development of improved drug formulations and delivery systems targeted directly to the affected ocular tissues-without preservatives, with controlled drug release-thereby enhancing treatment effectiveness, minimizing drug loss, and reducing patient risks associated with side effects and antifungal resistance. Furthermore, these advancements have the potential to significantly improve patient quality of life and increase the likelihood of full recovery, without irreversible visual impairment.
References
1. Burton MJ, Ramke J, Marques AP, Bourne RR, Congdon N, Jones I. The lancet global health commission on global eye health: vision beyond 2020. Lancet Glob Health. 2021 Apr;9(4):e489-551. doi: 10.1016/S2214-109X(20)30488-5, PMID 33607016, PMCID PMC7966694.
2. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 y and prevalence of avoidable blindness in relation to vision 2020: the right to sight: an analysis for the global burden of disease study. Lancet Glob Health. 2021 Dec 1;9(2):e144-60. doi: 10.1016/S2214-109X(20)30489-7, PMCID PMC7820391.
3. Whitcher JP, Srinivasan M. Corneal ulceration in the developing world a silent epidemic. Br J Ophthalmol. 1997 Aug;81(8):622-3. doi: 10.1136/bjo.81.8.622, PMID 9349145, PMCID PMC1722289.
4. Taipale J, Mikhailova A, Ojamo M, Nattinen J, Vaatainen S, Gissler M. Low vision status and declining vision decrease health related quality of life: results from a nationwide 11 y follow-up study. Qual Life Res. 2019 Dec;28(12):3225-36. doi: 10.1007/s11136-019-02260-3, PMID 31401749, PMCID PMC6863947.
5. Heesterbeek TJ, Van Der Aa HP, Van Rens GH, Twisk JW, Van Nispen RM. The incidence and predictors of depressive and anxiety symptoms in older adults with vision impairment: a longitudinal prospective cohort study. Ophthalmic Physiol Opt. 2017 Jul;37(4):385-98. doi: 10.1111/opo.12388, PMID 28516509.
6. Whitson HE, Cousins SW, Burchett BM, Hybels CF, Pieper CF, Cohen HJ. The combined effect of visual impairment and cognitive impairment on disability in older people. J Am Geriatr Soc. 2007 Jun;55(6):885-91. doi: 10.1111/j.1532-5415.2007.01093.x, PMID 17537089.
7. Yan C, Zhao H, Pan Q, Xie X, Chen K, Zhang L. Novel treatments for bacterial keratitis: a review. Int J Pharm. 2025 Aug 20;681:125793. doi: 10.1016/j.ijpharm.2025.125793, PMID 40446871.
8. Stapleton F. The epidemiology of infectious keratitis. Ocul Surf. 2023 Apr;28:351-63. doi: 10.1016/j.jtos.2021.08.007, PMID 34419639.
9. Ting DS, Ho CS, Deshmukh R, Said DG, Dua HS. Infectious keratitis: an update on epidemiology causative microorganisms risk factors and antimicrobial resistance. Eye (Lond). 2021 Apr;35(4):1084-101. doi: 10.1038/s41433-020-01339-3.
10. Ilyas M, Stapleton F, Willcox MD, Henriquez F, Peguda HK, Rayamajhee B. Epidemiology of and genetic factors associated with Acanthamoeba keratitis. Pathogens. 2024 Feb 4;13(2):142. doi: 10.3390/pathogens13020142, PMID 38392880, PMCID PMC10892102.
11. Burton MJ, Pithuwa J, Okello E, Afwamba I, Onyango JJ, Oates F. Microbial keratitis in East Africa: why are the outcomes so poor? Ophthal Epidemiol. 2011 Aug;18(4):158-63. doi: 10.3109/09286586.2011.595041, PMID 21780874, PMCID PMC3670402.
12. Brown L, Kamwiziku G, Oladele RO, Burton MJ, Prajna NV, Leitman TM. The case for fungal keratitis to be accepted as a neglected tropical disease. J Fungi (Basel). 2022 Oct 5;8(10):1047. doi: 10.3390/jof8101047, PMID 36294612, PMCID PMC9605065.
13. Hoffman JJ, Burton MJ, Leck A. Mycotic keratitis a global threat from the filamentous fungi. J Fungi (Basel). 2021 Apr 3;7(4):273. doi: 10.3390/jof7040273, PMID 33916767, PMCID PMC8066744.
14. Ali Shah SI, Shah SA, Rai P, Katpar NA, Abbasi SA, Soomro AA. Visual outcome in patients of keratomycosis at a Tertiary Care Centre in Larkana, Pakistan. J Pak Med Assoc. 2017 Jul;67(7):1035-8. PMID 28770882.
15. Roth M, Holtmann C, Daas L, Kakkassery V, Kurzai O, Geerling G. Results from the German fungal keratitis registry: significant differences between cases with and without a history of contact lens use. Cornea. 2021 Nov 1;40(11):1453-61. doi: 10.1097/ICO.0000000000002705, PMID 34633358.
16. Tananuvat N, Upaphong P, Tangmonkongvoragul C, Niparugs M, Chaidaroon W, Pongpom M. Fungal keratitis at a tertiary eye care in Northern Thailand: etiology and prognostic factors for treatment outcomes. J Infect. 2021 Jul;83(1):112-8. doi: 10.1016/j.jinf.2021.05.016, PMID 34038772.
17. Brown L, Leck AK, Gichangi M, Burton MJ, Denning DW. The global incidence and diagnosis of fungal keratitis. Lancet Infect Dis. 2021 Mar;21(3):e49-57. doi: 10.1016/S1473-3099(20)30448-5, PMID 33645500.
18. Yu B, Wang Q, Zhang L, Lin J, Feng Z, Wang Z. Ebselen improves fungal keratitis through exerting anti-inflammation anti-oxidative stress and antifungal effects. Redox Biol. 2024 Jul;73:103206. doi: 10.1016/j.redox.2024.103206, PMID 38796864, PMCID PMC11152752.
19. Benedict K, Gold JA, Smith DJ. Prevalence and features of fungal keratitis among US patients with commercial health insurance. JAMA Ophthalmol. 2024 Apr 1;142(4):386-8. doi: 10.1001/jamaophthalmol.2023.6825, PMID 38358752, PMCID PMC10870225.
20. Bala RK, Dange KJ, Patil GA. Practise and use of over-the-counter topical and traditional eye medicines and their effects in fungal keratitis cases in Tertiary Teaching Hospital in Northern India. Asian J Pharm Clin Res. 2024 Mar;17(3):103-6. doi: 10.22159/ajpcr.2024.v17i3.49534.
21. Bongomin F, Kwizera R, Namusobya M, Van Rhijn N, Andia Biraro I, Kirenga BJ. Re-estimation of the burden of serious fungal diseases in Uganda. Ther Adv Infect Dis. 2024 Feb 6;11:20499361241228345. doi: 10.1177/20499361241228345, PMID 38328511, PMCID PMC10848809.
22. Boakye Yiadom E, Odoom A, Osman AH, Ntim OK, Kotey FC, Ocansey BK. Fungal infections treatment and antifungal resistance: the sub-Saharan African context. Ther Adv Infect Dis. 2024 Nov 13;11:20499361241297525. doi: 10.1177/20499361241297525, PMID 39544852, PMCID PMC11562003.
23. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases estimate precision. J Fungi (Basel). 2017 Oct 18;3(4):57. doi: 10.3390/jof3040057, PMID 29371573, PMCID PMC5753159.
24. Gopinathan U, Garg P, Fernandes M, Sharma S, Athmanathan S, Rao GN. The epidemiological features and laboratory results of fungal keratitis: a 10 y review at a referral eye care center in South India. Cornea. 2002 Aug;21(6):555-9. doi: 10.1097/00003226-200208000-00004, PMID 12131029.
25. Donovan C, Arenas E, Ayyala RS, Margo CE, Espana EM. Fungal keratitis: mechanisms of infection and management strategies. Surv Ophthalmol. 2022 May-Jun;67(3):758-69. doi: 10.1016/j.survophthal.2021.08.002, PMID 34425126, PMCID PMC9206537.
26. Maier P, Betancor PK, Reinhard T. Contact lens associated keratitis an often underestimated risk. Dtsch Arztebl Int. 2022 Oct 7;119(40):669-74. doi: 10.3238/arztebl.m2022.0281, PMID 35912449, PMCID PMC9830382.
27. Aldave AJ, DeMatteo J, Glasser DB, Tu EY, Iliakis B, Nordlund ML. Report of the eye bank association of America medical advisory board subcommittee on fungal infection after corneal transplantation. Cornea. 2013 Feb;32(2):149-54. doi: 10.1097/ICO.0b013e31825e83bf, PMID 23051906.
28. Deka DS, Khanikar D. A study of the prescribing pattern and outcome of antimicrobials in infectious eye diseases in a Tertiary Care Hospital. Asian J Pharm Clin Res. 2024 Aug;17(8):67-70. doi: 10.22159/ajpcr.2024v17i8.51416.
29. Haseeb AA, Elhusseiny AM, Siddiqui MZ, Ahmad KT, Sallam AB. Fungal endophthalmitis: a comprehensive review. J Fungi (Basel). 2021 Nov 22;7(11):996. doi: 10.3390/jof7110996, PMID 34829283, PMCID PMC8623405.
30. Long C, Liu B, Xu C, Jing Y, Yuan Z, Lin X. Causative organisms of post-traumatic endophthalmitis: a 20 y retrospective study. BMC Ophthalmol. 2014 Mar 25;14:34. doi: 10.1186/1471-2415-14-34, PMID 24661397, PMCID PMC3987925.
31. Sadiq MA, Hassan M, Agarwal A, Sarwar S, Toufeeq S, Soliman MK. Endogenous endophthalmitis: diagnosis management and prognosis. J Ophthal Inflamm Infect. 2015 Dec;5(1):32. doi: 10.1186/s12348-015-0063-y, PMID 26525563, PMCID PMC4630262.
32. Henry CR, Flynn HW JR, Miller D, Forster RK, Alfonso EC. Infectious keratitis progressing to endophthalmitis: a 15 y study of microbiology associated factors and clinical outcomes. Ophthalmology. 2012 Dec;119(12):2443-9. doi: 10.1016/j.ophtha.2012.06.030, PMID 22858123, PMCID PMC3490005.
33. Reginatto P, Agostinetto GJ, Fuentefria RD, Marinho DR, Pizzol MD, Fuentefria AM. Eye fungal infections: a mini review. Arch Microbiol. 2023 May 15;205(6):236. doi: 10.1007/s00203-023-03536-6, PMID 37183227, PMCID PMC10183313.
34. Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clin Microbiol Rev. 2000 Oct;13(4):662-85. doi: 10.1128/CMR.13.4.662, PMID 11023963, PMCID PMC88956.
35. Sridhar J, Flynn HW JR, Kuriyan AE, Miller D, Albini T. Endogenous fungal endophthalmitis: risk factors clinical features and treatment outcomes in mold and yeast infections. J Ophthal Inflamm Infect. 2013 Sep 20;3(1):60. doi: 10.1186/1869-5760-3-60, PMID 24053550, PMCID PMC3848556.
36. LY V, Sallam A. Fungal endophthalmitis. In: Treasure Island, FL: StatPearls Publishing; 2023 Jun 26. PMID 32644683.
37. Natacyn. Nashville: Harrow IP, LLC; c2025.
38. Sharma N, Bagga B, Singhal D, Nagpal R, Kate A, Saluja G. Fungal keratitis: a review of clinical presentations treatment strategies and outcomes. Ocul Surf. 2022 Apr;24:22-30. doi: 10.1016/j.jtos.2021.12.001, PMID 34915188.
39. Swissvision. Fluconazole eye drops. Panchkula: Swissvision; 2025. Available from: https://www.swissvision.in/product/fluconazole-ee-drops. [Last accessed on 23 Jul 2025].
40. Al Badriyeh D, Neoh CF, Stewart K, Kong DC. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis. Clin Ophthalmol. 2010 May 6;4:391-405. doi: 10.2147/opth.s6374, PMID 20463910, PMCID PMC2866570.
41. Dawa Life Sciences. Vozole eye drops. Nairobi: Dawa Limited; 2025. Available from: https://dawalifesciences.com/product/vozole-eye-drops. [Last accessed on 23 Jul 2025].
42. Malhotra S, Khare A, Grover K, Singh I, Pawar P. Design and evaluation of voriconazole eye drops for the treatment of fungal keratitis. J Pharm (Cairo). 2014;2014:490595. doi: 10.1155/2014/490595, PMID 26556196, PMCID PMC4590801.
43. Jain K, Garhwal J, Swami T. Clinical profile and evaluation of topical voriconazole for management of fungal corneal ulcer in North Western Rajasthan. Delhi J Ophthalmol. 2018;29(1):35-8. doi: 10.7869/djo.374.
44. Sharma N, Bagga B, Singhal D, Nagpal R, Kate A, Saluja G. Fungal keratitis: a review of clinical presentations treatment strategies and outcomes. Ocul Surf. 2022 Apr;24:22-30. doi: 10.1016/j.jtos.2021.12.001, PMID 34915188.
45. Sahay P, Asif MI, Maharana PK, Titiyal JS. Periocular contact dermatitis with use of topical voriconazole 1% in mycotic keratitis. BMJ Case Rep. 2018 Sep 15;2018:bcr2018226498. doi: 10.1136/bcr-2018-226498, PMID 30219785, PMCID PMC6144350.
46. World Medicine Pharmaceutical Company. Fluzamed 0.3% Eye Drop. Istanbul: World Medicine Ilac San. Ve Tic A. S.; 2025. Available from: https://www.worldmedicine.com/translator/en/products/medicines?searchField=name&search=fluzamed. [Last accessed on 23 Jul 2025].
47. Lexicare Pharma Pvt. Ltd. Fluconazole eye/ear drop. Ankleshwar: Lexicare Pharma Pvt. Ltd; 2025. Available from: https://www.lexicarepharma.com/fluconazole-eye-ear-drop-5422867.html. [Last accessed on 02 Sep 2025].
48. International I. Fluconazole eye drops/ophthalmic solution 0.5%. In: Hangzhou: Inopha International Co, Limited; 2025. Available from: https://www.inopha.net/fluconazole-eye-drops-ophthalmic-solution-0-5. [Last accessed on 02 Sep 2025].
49. Sunways (India) Private Limited. ZONAT natamycin 5% eye drops. Mumbai: Sunways (India) Private Limited; 2025. Available from: https://zonatophthalmicsuspension|leadingeyecarespecialistsinindia|sunwaysindiapvtlt. [Last accessed on 02 Sep 2025].
50. Care NRIV. Nata-aid eye drop. New Delhi: NRI Vision Care India. LTD; 2025. Available from: https://nriglobalhealthcare/detail.com.jsp?cc=105andsrsltid=afmboortfi1xf8mkmueipliikbkebkyxfh1anghwhao0eanl8zhiup9c.
51. Makangara Cigolo JC, Oladele RO, Kennedy SB, Bignoumba M, Hassane HM, Bucumi V. Diagnostic capacity for fungal keratitis in Africa survey in 50 African countries. Ocul Surf. 2023 Oct;30:139-41. doi: 10.1016/j.jtos.2023.08.010, PMID 37660991.
52. Khor WB, Prajna VN, Garg P, Mehta JS, Xie L, Liu Z. The Asia cornea society infectious keratitis study: a prospective multicenter study of infectious keratitis in Asia. Am J Ophthalmol. 2018 Nov;195:161-70. doi: 10.1016/j.ajo.2018.07.040, PMID 30098351.
53. Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013 Jun;73(9):919-34. doi: 10.1007/s40265-013-0069-4, PMID 23729001.
54. Manzouri B, Vafidis GC, Wyse RK. Pharmacotherapy of fungal eye infections. Expert Opin Pharmacother. 2001 Nov;2(11):1849-57. doi: 10.1517/14656566.2.11.1849, PMID 11825321.
55. O Day DM, Head WS, Robinson RD, Clanton JA. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res. 1986 Nov;5(11):877-82. doi: 10.3109/02713688609029240, PMID 3490954.
56. Betbeze CM, Wu CC, Krohne SG, Stiles J. In vitro fungistatic and fungicidal activities of silver sulfadiazine and natamycin on pathogenic fungi isolated from horses with keratomycosis. Am J Vet Res. 2006 Oct;67(10):1788-93. doi: 10.2460/ajvr.67.10.1788, PMID 17014335.
57. Mascarenhas M, Chaudhari P, Lewis SA. Natamycin ocular delivery: challenges and advancements in ocular therapeutics. Adv Ther. 2023 Jun;40(8):3332-59. doi: 10.1007/s12325-023-02541-x, PMID 37289410.
58. Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol. 2013 Apr;131(4):422-9. doi: 10.1001/jamaophthalmol.2013.1497, PMID 23710492, PMCID PMC3769211.
59. Alakkad A, Stapleton P, Schlosser C, Murdan S, Odunze U, Schatzlein A. Amphotericin B polymer nanoparticles show efficacy against candida species biofilms. Pathogens. 2022 Jan 7;11(1):73. doi: 10.3390/pathogens11010073, PMID 35056021, PMCID PMC8781556.
60. Bongomin F, Oladele RO, Gago S, Moore CB, Richardson MD. A systematic review of fluconazole resistance in clinical isolates of cryptococcus species. Mycoses. 2018 May;61(5):290-7. doi: 10.1111/myc.12747, PMID 29377368.
61. Schulz J, Kluwe F, Mikus G, Michelet R, Kloft C. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metab Rev. 2019 Aug;51(3):247-65. doi: 10.1080/03602532.2019.1632888, PMID 31215810.
62. Suman S, Kumar A, Saxena I, Kumar M. Fungal keratitis: recent advances in diagnosis and treatment. In: Rodriguez Garcia A, C Hernandez Camarena J, editors. Infectious eye diseases recent advances in diagnosis and treatment. Intech Open; 2021. doi: 10.5772/intechopen.98411.
63. Habib FS, Fouad EA, Abdel Rhaman MS, Fathalla D. Liposomes as an ocular delivery system of fluconazole: in vitro studies. Acta Ophthalmol. 2010 Dec;88(8):901-4. doi: 10.1111/j.1755-3768.2009.01584.x, PMID 19681761.
64. Aldosari BN, Ibrahim MA, Alqahtani Y, Abou El Ela AE. Formulation and evaluation of fluconazole nanosuspensions: in vitro characterization and transcorneal permeability studies. Saudi Pharm J. 2024 Jul;32(7):102104. doi: 10.1016/j.jsps.2024.102104, PMID 38841107, PMCID PMC11152688.
65. Daneshnia F, De Almeida Junior JN, Ilkit M, Lombardi L, Perry AM, Gao M. Worldwide emergence of fluconazole resistant Candida parapsilosis: current framework and future research roadmap. Lancet Microbe. 2023 Jun;4(6):e470-80. doi: 10.1016/S2666-5247(23)00067-8.
66. Sigera LS, Denning DW. Flucytosine and its clinical usage. Ther Adv Infect Dis. 2023 Apr 5;10:20499361231161387. doi: 10.1177/20499361231161387, PMID 37051439, PMCID PMC10084540.
67. Bakhrushina EO, Anurova MN, Demina NB, Lapik IV, Turaeva AR, Krasnuk II. Ophthalmic drug delivery systems. Razrabotka i Registracia Lekarstvennyh Sredstv. 2021;10(1):57-66. doi: 10.33380/2305-2066-2021-10-1-57-66.
68. Ivanov IS, Bakhrushina EO, Turaeva AR, Shatalov DO, Aydakova AV, Akhmedova DA. Approaches to the search of the optimum packaging of eye drops. Int J App Pharm. 2022;14(5):1-7. doi: 10.22159/ijap.2022v14i5.45402.
69. Wu Y, Liu Y, Li X, Kebebe D, Zhang B, Ren J. Research progress of in situ gelling ophthalmic drug delivery system. Asian J Pharm Sci. 2019 Jan;14(1):1-15. doi: 10.1016/j.ajps.2018.04.008, PMID 32104434, PMCID PMC7032175.
70. Kolawole OM, Cook MT. In situ gelling drug delivery systems for topical drug delivery. Eur J Pharm Biopharm. 2023 Mar;184:36-49. doi: 10.1016/j.ejpb.2023.01.007, PMID 36642283.
71. Choursiya K, Kandalkar S, Shaikh S, Gangurde P, Jadhav K, Nikam S. Advancements in ocular drug delivery system: a comprehensive review. Int J Pharm Sci. 2024 May 16;2(5):758-75. doi: 10.5281/zenodo.11204180.
72. Roche M, Lannoy D, Bourdon F, Danel C, Labalette P, Berneron C. Stability of frozen 1% voriconazole eye drops in both glass and innovative containers. Eur J Pharm Sci. 2020 Jan 1;141:105102. doi: 10.1016/j.ejps.2019.105102, PMID 31655210.
73. Mughal S, Sakina SK. Artificial tears: promising treatment or silent threat to public health. Health Sci Rep. 2023 Aug 24;6(8):e1508. doi: 10.1002/hsr2.1508, PMID 37636283, PMCID PMC10448608.
74. Lopez Cano JJ, Gonzalez Cela Casamayor MA, Andres Guerrero V, Herrero Vanrell R, Molina Martinez IT. Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection. Expert Opin Drug Deliv. 2021 Jul; 18(7):819-47. doi: 10.1080/17425247.2021.1872542.
75. Singh M, Bharadwaj S, Lee KE, Kang SG. Therapeutic nanoemulsions in ophthalmic drug administration: concept in formulations and characterization techniques for ocular drug delivery. J Control Release. 2020 Oct 13;328:895-916. doi: 10.1016/j.jconrel.2020.10.025, PMID 33069743.
76. Zhang J, Chen H, Jhanji V, Zhang B, Xie L, Dong Y. Clinical characteristics and treatment outcomes of pediatric fungal keratitis. Infect Drug Resist. 2025 Mar 4;18:1271-8. doi: 10.2147/IDR.S507178, PMID 40059941, PMCID PMC11890013.
77. Jiang T, Tang J, Wu Z, Sun Y, Tan J, Yang L. The combined utilization of chlorhexidine and voriconazole or natamycin to combat fusarium infections. BMC Microbiol. 2020 Sep 5;20(1):275. doi: 10.1186/s12866-020-01960-y, PMID 32891143, PMCID PMC7487579.
78. Al Hatmi AM, Meletiadis J, Curfs Breuker I, Bonifaz A, Meis JF, De Hoog GS. In vitro combinations of natamycin with voriconazole itraconazole and Micafungin against clinical Fusarium strains causing keratitis. J Antimicrob Chemother. 2016 Apr;71(4):953-5. doi: 10.1093/jac/dkv421, PMID 26702918.
79. Hoffman JJ, Arunga S, Matayan E, Ebong A, Orishaba F, Makupa W. Randomised controlled trial of topical combination therapy chlorhexidine 0.2% and natamycin 5% versus topical natamycin 5% alone for fungal keratitis in East Africa: study protocol. Wellcome Open Res. 2025 Mar 28;10:165. doi: 10.12688/wellcomeopenres.21390.1, PMID 40495927, PMCID PMC12149813.
Published
How to Cite
Issue
Section
Copyright (c) 2026 ILYA KURGUZOV, IRINA LOGUNKOVA, ELENA BAKHRUSHINA, MADINA DURZHINSKAYA, ANNA PLYUKHOVA, ALEXANDRA KURGUZOVA, MARIA NARBUT
This work is licensed under a Creative Commons Attribution 4.0 International License.